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The ability of melanOlna to develop resistance to 
mitotoxins, growth-factor- directed anti-neoplastic 
agents that offer potential for the treatment of this 
highly refractory disease, may limit therapeutic effi-
cacy. To address this problem, we developed a sub-
cloned human melanoma cell line that is resistant to 
the mitotoxin composed of basic fibroblast growth 
factor conjugated to the ribosome-inactivating pro-
tein saporin. Resistance was caused by autocrine FGF 
ligands, which down-regulate bFGF receptors and 
reduce bFGF-saporin binding. Inhibiting the auto-
T he mitotoxin basic fibroblast growth factor (bFGF)-saporin is a hybrid cytotoxic prote in composed of bFGF covalently coupled to a ribosomal toxin that offers a novel approach for the treatment of neoplas-tic disease . T his mitotox in attaches to the cell -surface 
growth factor receptor via the ligand and internalizes by receptor-
mediated endocytosis; upon its release into the cytopl asm by the 
lower pH of the endosome, the saporin moiety ca.talytica Lly in.b.ibits 
protein synthesis by rendering the 60-S subunit of ribosomes unable 
to bind elongation facto r 2, thus mediating cell death [1]. T lus 
approach m ay have therapeutic utility for the trea tment of malig-
nant melanoma, in part beca use bFGF recepto r expression in most 
nonproliferating normal cells appears to be very limited [2] and 
beca use m any melanoma cell lines express hjgh-affiluty receptors 
for bFGF [3] . G iven the refractory nature of melanoma to tradi-
tional therap y and the potent cytotoxicity of bFGF-saporin that we 
and others have demonstrated fOf melano ma cells both in vitro and 
ill Vi llO for xenograft and m etasta tic mo dels [4,5], bFG F-saporinmay 
o ffer a new strategy in chem otherapy. 
As with convention al chemotherapeutic agents , however, effec-
tive treatment m ay be limi ted by the em ergence of resistant tumor 
cell populations. T umors eventu ally fecur in xenografted mjce, and 
up to 40% appea r resistant to furth er therapy with bFGF-saporin 
(unpublished o bservations). As bFGF-sapori.n moves closer to 
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crine loop with suramin or with neutralizing antibod-
ies to FGF up-regulated receptors and decreased 
resistance in vitro. Furthermore, suramin restored 
sensitivity in resistant tumor xenografts. These re-
sults suggest the potential of therapeutic modalities 
combining agents that neutralize growth factors witli 
receptor-directed mitotoxins .for targeting malignant 
melanoma either to prevent emergence of resistance 
or to circumvent resistance once it occurs. Key words: 
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clinical trials, it becom es in creasingly important to understand 
resistance and to devise strategies for combating ,resistance. Beca use 
production of mitotoxin-resistant cells has been described by other 
investigators [6-9], these strategies might be widely applicable to 
other mitotoxin conjugates or immunotoxin conjugates as w ell. 
W e report here that subpopulations of human melanoma cells 
escape bFGF-saporin targeting becau se of a bFGF autocrine loop, 
and we provide evidence that t1us endogeliolls bFGF down-
regulates bFGF receptors on these cells, thus reducing their avail-
abi li ty for nutotoxin binding and subsequent cytotoxicity . W e 
demonstrate that t1us mode of resistance may be circumvented by 
using agents such as suramin or ne utralizing antibodies to FGF, 
which block the alltocrine loop and up-regulate receptors, be fore 
treatment with bFGF-saporin to restore sen sitivi ty ill villo and ;11 
lIitro . 
MATER.1ALS AND METHODS 
Mitotoxin bFGF-sa porin was a generous gift from D.A. Lappi and A. 
Baird (The Whittier Institute, La J olla, CAl. Saporin was conjugated to 
bFGF using N-succinimidyl-3(2-pyridydithio)proprionate, and the conju-
gate was purified by hepa rin-sepharose and chromatography, as described 
L 10,1 1). 
Dcvclopmcnt and Cloning of bFGF-Saporin-Rc.istant CcIls SK-
MEL-5 cells (American Type C ul ture Collection, Rockvi lle, MD) were 
subjected to increasing selective pressure ill lIilro using a procedure adapted 
from Teicher and Frei [1 2]. Briefly, semiconfluent SK-MEL-5 cell s growing 
in minimum essential mediul11 (Gibco-BRL, Grand Island , NY) supple-
mented with 10% fetal bovine se rum (Gibco-BRL) and antib iotics were 
trea ted overnight with 10 nM bFGF-sa porin (suffi cient to kill approximately 
90% of the cdls). After treatment, the ce ll s were washed three times with 
phosphate-buffered sa line (PBS), £i'esh medium was added, and incubation 
of cells was contin ued . Each time the cells reached app roxima te ly 75% 
confluence, bFG F-saporin was adm inistered in a dose escalated 15'\1" Ii'om 
the prev io us treatment. When o vernight treatment with 40 nM bFGF-
saporin was reached , surviving cell s were recovered and grown in medium 
supplemented with 10% feta l bovine serum and 2 nM bFGF-saporin to 
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maintain se lective pressure. After "pproximately I year of treatment. 
including 1 m onth of growth in the constant presence of bFGF-saporin. 
resistant ce ll s were cloned by limi ting dilution w ithout bFGF-saporin . One 
colony. FSB4. w"s expanded in the absence of bFGF-saporin selective 
press ure for 2 months. Subsequent bFGF-saporin survival assays revealed 
that it had reta ined resistance desp ite the absence of selective pressure. 
Doubling time for the FSB4 clone was approximately 18 h, compared w ith 
approximHtely 22 h for the parental SK-MEL-5. 
Colony Formation Assay Subconlluent ce ll monolayers, seeded Ht a 
concentration of 2 X :10' cells/cm2, we re mHin tained overnigh t in supple-
m ented minimu111 essentia l medium as above. T he fo llowing day, the cells 
were washed with medium and th en exposed to bFGF-saporin (5-150 nM) 
or saporin (25- 1000 nM) for 1 h in serum-free medium. After treatment, the 
cell s were washed three times with fresh medium. suspended by treatment 
w ith trypsin /ethylenediHm ine tetraacetic acid , and reseeded at 3 X 103 
ce lls/cm 2 in dup li cate . After 7 d, colonies were coun ted . Results arc 
reported as the concentration of bFGF-saporin or saporin tha t resulted in 
50'% reduction in colonies. Results from three independent experiments 
were paired by treatmen t and analyzed using the pHired Wilcoxon test 
(Instat; GrHph Pad, San D iego, CA) . 
b F GF Receptor Cross-Linking Studies C ross-linking of 12s l_bFGF 
(Amersham. Arlington H eights, IL) to receptors o n cells (2 X 105) from 
SK-MEL-S parent and FSB4 resistant lines w ith 0.15 mM disuccinimidyl-
suberate (OSS; Boehringer-Mannheim. Indianapo li s. IN) was performed 
using the method o f Yayon e( at [1 3]. Cell extracts (from equivalent 
n umbers of ce ll s) we re resolved by 7'Yo sod ium dodecylsu lf.1te polyacryl-
amide ge l electrophoresi s (SOS-PAGE) under reducing conditions. and 
bFGF recepto rs were visualized by autoradiography using Kodak XAR-5 
presensitized fi lm with Lightning Plus intensifying screens at - 70°C for 1-8 d. 
bFGF R eceptor Assay 12s l_bFGF binding was performed usin g a radio-
receptor assay as described by Moscatelli [14). Briefly. ce lls growing in 
six-well plates were washed with PBS and incubated with serum-free 
D ulbccco's modified Eagle's medium conta ining O. IS% ge latin and 25 mM 
HEPES (N-2-hydroxyethylpiperazine-N ' -2-ethanesu lfoni c acid) (PH 7.4) 
fo r 1 h at 37°C. Afte r 1 h , the m edium was replaced w ith fresh m edium 
containing 125 I_bFGF (S-SO ng/ml). After 2 h at 4°C on a platform rocker. 
th e cell s were washed o nce w ith co ld PBS and twice w ith 2 M NaCI in 20 
mM HE PES (pH 7.4) to remove 125 1_bFGF bound to extracellular matrix 
(low-affinity receptors) (1 4). 125I_bFGF bound to high-attlni ty receptors was 
re leased by two subsequent washes w ith 2 M NaCI in 20 mM sodium 
acetate (pH 4 .0). Nonspecific binding was determined in the presence of 
SOO-fold excess of unlabeled bFGF. R eleased radioactivity was quantitated 
in a gamma scintillatio n counter (MULTI-PKI AS; Packard Instrument . 
Sterling, V A). 
bFGF Competition Assay SK-MEL-S and FSB4 cells were seeded into 
96-well tissue cul ture plates (Costar, Cambridge, MA) at 103 cells/well. 
T he next day. the medium was removed and medium containing bFGF-
saporin (1-5000 pM) or bFGF-saporin with 100-fold excess bFGF (0.1-500 
nM) was added to the we lls. Cell s in triplicate well s were cultured for 72 h 
w ith bFGF-sapo,-in. Surviving cell s were counted using a Coulter Counter 
(Coulter Electronics. Inc., Hialeah, FL). 
Detection of bFGF Receptor Proteins Receptor proteins were puri-
fied from 5 X 10(' cell s by microbatch afri ni ty chromatography on the C-l S 
polyclona l jig an tibody (specific for FGFKI ; San ta C ru z Biotechno logy, 
Inc., Santa C ru z, CA), linked to sepharose beads, solubilized by boiling in 
sodium dodecylsu lf.1te (SOS) sample bufFer w ith reducing re"gents, and 
resolved by 7.5% SDS-PAGE. The receptor proteins we"e transferred to 
nitrocellulose filters and incubated with C-1S antibod), (2 p.g/ ml) , the fi lters 
were washed. and bound proteins were visuali zed by enhauced chemilumi-
nescence. as directed by the man ufacturer (Amersham) . As a control, 
SK-M~EL-5 cell s were incubated with peptide sc-121P (Santa C ruz Biotech-
nology. Inc. ) capable of blocking anti~j1g binding. 
Suramin and Nentralizing Antibodies in Cell Snrvival Assays Me-
dium on subconfluent mo no layers of parenta l o r res istant cells was rep laced 
with fres h serum- fi'ee medium with or without suramin (1 mM) (FBA 
Pharmaceutica ls, New York, NY) or neutrali zing antibodies (10 mg/ I) to 
bFGF (Upstate B iotechnology, Inc., LIke Placid . NY) and /or to acid ic FGF 
(aFGF) (K&O Systems, Minneapolis. MN). Fifteen hours later, the medium 
was removed and the cel ls were washed tlu'ee times with unsupplemented 
medium before exposing cells to bFGF-saporin (5-1S0 nM) fo r 1 h in 
serum-free medium. After treatment, the cell s were processed as in the 
colony assays described above, except that individ ual ce ll s were counted. 
It.esults from three independent experiments were anal yzed by the paired 
Wilcoxon test using Instat. 
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Detection of bF GF Intracellnlar and Extracellnlar Protein To 
detect intracellu lar bFGF, we isolated bFGF from extracts of80% confluent 
cultures of parent and resistant cells using affinity chromatography on bFGF 
monoclonal antibody (Santa Cruz Biotechnology. Inc.) that had been 
covalently coupled to Protein A Sepharose CL-4B (Phannacia LKB Bio-
teclm o logy, Inc.) using dimethylpemilimidate (Sigma) . To detect extracel-
lular bFGF. cultures of parent and resistant cell s were serum starved for 8 h 
and then incuba ted overnight in serum-free m edium with bFGF-neutraliz-
ing antibody (UB I) covalen tly coupled to Protein A Sepharose CL-4B. 
bFGF was elu ted from the immunosorbcnt as above. T he intrace llular and 
extracellular samples of bFGF and. as a control, 1 ng ofhumaJl recombinant 
bFGF (Amersham), were reduced and alkylated (with 0.2 M N-ethylmale-
imide [1 5]) before resolving the proteins by 12% SDS-PAGE. T he proteins 
were transferred clectrophoretically onto nitrocellulose (Hybond; Amer-
sham). which was probed using antibody to bFGF (2 p.g/ml) (Santa Cruz 
Biotechnology, Inc.) and visualized by chemi luminescence as above. 
I" Vivo Antitunlor Stndies Cell s from parental and resistant I.ines 
growing in culture w ere implanted subcutaneously into the right rear flanks 
of8-week-old male Balb/c nu / nu mice at a concentration of2 X 10" ce ll s 
in 0. 1 ml of unsupplemented minimum essentia l medium on day O. Nude 
mice were bred and maintained by the Roger W illiam s Cancer Center 
Animal Care Faci li ty in accordance with institutional guidelines. For a.ll 
studies, bFGF-saporin was dissolved in steri le pBS/O. 1 0;., bovine serum 
albumin, and treatment (31-125 p.g/kg) was delivered by in tr>1Venous tail 
injection 5 d after implan tation , when the tumors were approximately 50 
mm3 • For studies combining bFGF-saporin with suramin. suramin was 
disso lved in sterile PBS. and treatment (150 mg/ kg) was delivered by 
intravenous tail injection on days 1-3 before bFGF-saporin treatment (62 
f.l,g /kg) on day S. T he progress of each tumor was measured at least twice 
weekly, and tumor volumes were calculated using the fOn1mla: Volume = 
[(minimum m easurement)2 (maximum measurement)] /2 [16]. Median tu-
mor vo lumes for the various treatment groups were compared by Instat 
using the Krll ska l-Wallis nonparametric test, fo llowed by Dunn post-tests 
to compare the effects of vario us treatments. 
RESULTS 
Development of an SK-MEL-5 Subclone Resistant to bFGF-
Saporin [/I II j/m, a bFGF-saporin resistant cell line was deve loped 
by system atic dose escalatio n and was clon ed by limiting di lu tion. 
Cell surv iva l was d etermined in colo n y-formation assays for paren-
tal SK-MEL-5 and the cloned resistant subline. FSB4, exposed to 
va rio u s concentratio n s ofbFGF- saporin o r saporin aJone. The 50% 
inhibi to ry con centration (IC so) (150 nM) for bFGF-saporin in 
cloned FSB4 cell s was sixfo ld hig h e r than th e IC so (25 nM) for the 
parental SK-MEL-5 cell li.ll e (p < 0.01). Treannent w ith saporin 
a lone demonstrated o nly minim al cytotOl";city, with ICsos of 900 
nM o r g reater in b oth cell lines; th e FSB4 resistant line d e mon-
strated a sligh t increase in sensitiv ity comp ared with the parenta.! 
line. By colo n y-form atio n assays. sen sitiv ity to bFGF-saporin re-
turned g radua lly over 3- 5 m o n th s in th e absence of se lective 
pressure (data not sh own). 
The Resistant Clone Displays Fewer bFGF Receptors Pre-
liminary studies have su ggested a direc t correla tion between th e 
sensitiv ity of cell s to bFGF-saporin and the number of FGF 
receptors per cell [1 0] ; therefore, we hypothesized that bFGF-
saporin resistance might b e attributed to reduced expression ofFGF 
receptors . To test this h ypoth esis, we cross-linked 125 J_bFGF to 
FGF receptors with DSS. SDS-PAGE an a lysis revealed a broad. 
1.45-170-kDa baJ~d (Fig 1) con sisten t in size w ith that expected for 
bFGF cross-linked to FGF receptors [17]. Den sitom etric ana.!ysis of 
this band in three re peated experime nts sh owed 0% to 25% as much 
receptor in FSB4 clone d cell s as in th e parental SK-MEL-5 cell line . 
We o bserved an interesting in c rease in hig h-afrinity bFGF receptors 
that paralle led th e loss of resistance during prolonged (3-5 months) 
culture in the absence of b FGF- sap orin selective pressure, consis-
tent w ith o ur d evelo ping h ypoth esis that a d ecrease in FGF receptor 
numbers was resp onsible for bFGF-saporin resistance. 
By 12SI_bFGF radioreceptor assay, parental SK-MEL-5 cells h ad 
approximately 23,000 hig h -affinity binding sites per cell by Scat-
c hard an a lys is [1 8 ] , simil ar to previously deternlined va lues [3]. 
Con sistent with the reduced receptor cross-linking of FSB4 cells 
(Fig 1) and th e ir redu ced 125 1_bFGF binding, th e resistant cell s 
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Figure 1. Resistant cells display markedly reduced amounts ofFGF 
receptors by cross-linking of 125I _bFGF. Cells were aUowed to bind 
1251_bFGF for 2 h at 4°C with or without a 200-fold excess of unlabeled 
bFGF. Unbound 1251_bFGF was washed away, and bound 125[_bFGF was 
cross-linked using DSS to the FGF receptors. The cross-linked complexes 
were extracted from the ce lls, analyzed by 7% SDS-PAGE under reducing 
conditions, and visualized by autoradiography. Brace indicates position of 
the 145-170-kDa band. 
displayed only approximately 7000 high-affinity receptors per cell , 
with little apparent change in dissociation constant (K,,) (155 pM) 
from the parental line (130 pM). Resistant FSB4 cells also expressed 
one third fewer low-affinity receptors (approximately 400,000) 
than parental cell s (approximately 600,000) (Fig 2B). 
Exogenons bFGF Renders the Parental Cells Insensitive to 
bFGF-Saporin and Down-Regulates bFGF Receptors It is 
interesting that a 100-fold excess of bFGF, which competes with 
bFGF-saporiJl for binding to FGF receptors [9], shifted the parenta l 
survival curve (p < 0.002) to nearly coin cide with that of the FSB4 
cell s (p > 0 .05) (Fig 3A). In light of these results and because 
autocrine bFGF has a major role in the transformation and growth 
of melanoma cells [19], we hypothesized that excessive bFGF 
produced by FSB4 cells mi ght be down-regulating bFGF receptors. 
Consistent with this possibility, chroni cally exposing parental cells 
to exogenous bFGF down-regulated receptors, an effect that could 
be reversed within 24 h by removing the exogenous bFGF from 
culture (Fig 3B) . 
Blocking Autocrine bFGF Increases bFGF Receptors and 
Abrogates bFGF-Saporin Resistance To test w hether auto-
crine growth factors might be similarly down-regulating bFGF 
receptors and ca using bFGF-sapo rin resistance in FSB4 cells, we 
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Figure 2. Resistant cells display reduced numbers ofFGF receptors 
by Scatcha.rd analysis. 125 I_bFGF binding to parental SK-MEL-5 (opell 
circles) and to the resist'lI1t FSB4 (closed circles) ce lls was determined by 
radioreceptor assay [1 4]. Low-aflinjty binding (B) was designated as the 
amoun t of 1251_bFGF released from the extracel lular matrix by hjgh-salt 
washes at pH 7.4. High-allinity binding (A) was des ignated as the amount 
of 1251_bFGF released by subsequent high-salt washes at pH 4.0. Nonspe-
cific binding was determined in the presence of500-fold excess of un label cd 
bFGF. The data arc shown as Scatchard plots . B/F, rati o of bound 
125 1_bFGF to unbollnd 1251_bFGF. 
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Figure 3. Exposure to exogenous bFGF reduces parental expres-
sion of bFGF receptors and renders the parental cells resistant to 
bFGF-saporin. A. SK-MEL-5 resistance to bFGF-saporin (SAP) (0.001-5 
nM) in the absence (opell circlcs) or presence (closed circles) of 1 OO-fold excess 
ofbFGF; FSB4-resistant ce ll s were exposed to bFGF-saporin in the absence 
(ojJe,., sqlla/'cs) or presence (closed squares) of 1 OO-fold excess bFGF. After 3 d 
of treatment, the cells were suspended by trypsin ization and counted by 
Cou lter Counter. Resu lts arc expressed as the mean survi ving fraction of 
treated ce lls normaLized to mcdia controls (n = G). Bars, SEM. B, the 
amount of high-afEnjty bFGF receptor ou parental ccll s is reduced by 
exposure to exogcnous bFGF. SK-MEL-5 parenta l ce ll s werc cultured for 
24 h in the prcsence of recombinant bFGF ('18 ng/ml), thcn for an additional 
24 h in the presence or absence (hours + 1- ) ofbFGF. 125I_bFGF binding 
and cross-linking to these ccll s was performed as in Fig 1. Brace indicates 
position of the 145-170-kDa band. 
first examined the expression of FGF receptor type-I (fig) in 
SK-MEL-S and FSB4 with or without pretreatment with suramin , a 
polyanionic compound that b locks growth factor binding to recep-
tors [20-23]. Receptor immunoblotting revea led receptor-sp ecific 
proteins of 90 kDa, 110 kDa, 130 kDa , and 150 kDa in both 
SK-MEL-S and FSB4 cells; however, the resistant FSB4 cells 
conta ined a larger proportion of bFGF receptor as the 110-kDa 
protein (Fig 4) . By pulse cha se ana lys is, the 90-kDa protein 
appeared to be a precursor of the 130-kDa and lSO-kDa receptor 
prote ins, whereas the 110-kD" protein appeared to be a degrada-
tion prod uct of the mature, lS0-kDa and 130-kDa bFGF receptors 
(data not shown) . Exposure to suram in for 15 h in c)'eased the 
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Figure 4. Suranlin treatment of resistant cells increases their 
expression of high-molecular-weight bFGF receptor. Parental SK-
MEL-5 cells or the resistant FSB4 ce ll s were cultured fo r 15 h in the 
presence (+ ) or absence (- ) of l mM suramin. bFGF receptors were 
il11l11unoprecipi tated with antibody to the receptors (anti-fig) and analyzed 
by chel11ilul11inescent anti~flg il11l11unoblotting. As a con tJ'OI , SK-MEL-5 
cells were incubated with a control peptide (Cp) c;lpable of blocking anti~flg 
binding. T he positions of molecular-weight standards are indicated. A rmll's 
indicate positions of the 150-kDa and 130-kDa FGF receptors (fig) and of a 
110-kDa putative degradation pJ'Oduct. 
inte n sity of the 150-kDa receptor while decreasing intensity of the 
130-kDa receptor and the 1l0-kDa " degradation " product. Con-
sistent with b oth these d ata and o ur d eveloping hy poth es is of 
autocrine-drive n resistance to bFGF- saporin , pretreatment with 
suramin had littl e e ffect on the bFGF-saporin sensit iv ity of parental 
cells ill lIil.ro. H owever, suramin reduced by approximately 60-fold 
t he con centration of b FGF- saporin required to yie ld a 50% inhibi-
tio n in FSB4 survival (Fig SA) (p < 0 .0001). It is n oteworth y that 
this re ndered FSB4 cells nearly 10 times more sensitive than 
parental cells to bFGF-saporin. 
To determine whether suram in mig h t be exerting its effects by 
complexing with auton'ine bFGF, we tested w he ther' n eutral izing 
antibody to bFGF would similarly restore bFGF-saporin sensitiv ity 
to FSB4 ce lls. SK-MEL- 5 and FSB4 cell s w e re treated overnight 
with n e u tra liz ing antibody sp ccifrc for human b FGF, washed , and 
then treated with bFGF- sapo rin . T his pretreatmen t iJlc reased th e 
bFGF-saporin sen sitivity of FSB4 cells so that the ir 7-d surv ival 
curve was indisting uishable liOln that of the parental cell tin e (Fig 
SB) (p > 0.1) . Taken togeth er, t hese resul ts suggest tha t suramin 's 
ability to restore bFGF-sap orin sen sitiv ity to resistant FSB4 ceUs 
occurs, at least in part, from its ab ili ty to bl ock th e interactio n 
between endogeno us bFGF and its receptor. However , res istant 
cells pretreated with bFGF n eutraliz ing antibody did not de m o n-
strate the h ypersensitivi ty engendered by suramin . Perhaps tlle 
resistant ceUs constitutively secreted an oth er g rowth factor in 
addi tion to bFGF capable of compe ting for bFGF receptors. A likely 
candidate is aFGF, inasmu ch as both aFGF and b FGF bind w ith 
hig h aftinity to FGF receptor type-l (fig) and to FGF receptor type- 2 
(bek) [24] . A lth o ug h pre treatme n t of parental SK-MEL-5 cells with 
n e u tra lizing an tibody to bFGF did not allect th e ir sen sitivi ty to 
bFGF- saporin , pretreatment with n e u tra liz ing antibody specific for 
aFGF increased the ir sensitivity, su gges ting th at aFGF partially 
inhibi ts bFGF-sapo rin bindin g and cytotoxic ity in parental cell s 
(Fig SB) . Similarly, pre treatm ent of FSB4 resistan t cells w ith 
neutrali z ing antibody to aFGF in creased th e ir sensitiv ity to b FGF-
saporin severa lfo ld (p < 0.0001) . Combining ne u tra liz ing antibod-
ies to aFGF and b FGF for pre treatme n t of FSB4 cells furt he r 
in creased FSB4 sen sitiv ity (p < 0 .0001) , comparabl e to FSB4 cells 
treated w ith suramin and to parental cells treated with n eutraliz ing 
antibody to aFGF alone or the combina tio n of n e utra li z ing anti-
bodies to aFGF and bFG I~. T h ese findin gs suggest that both pare n ta l 
and resistant cells pro du ce au toerinc FGFs; however, though 
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a u tocrine aFGF plays a role in decreasing bFGF-saporin sensitivity 
in b oth cell lines, autocrin e bFGF is responsibl e for the differentia l 
sensitivity to bFGF-saporin observed between SK-MEL-5 parental 
ceUs and FSB4 resistan t cells. 
Comparison of Endogenous bFGF in Resistant and Parental 
Cells T h ese results also su ggested th at resistant FSB4 cells som e-
h ow diffe r in their expressio n of bFG F compared with pa.rental 
SK-MEL-5 ceUs. To investigate tlus fu r th er, we purified b FGF from 
SK-MEL-5 o r FSB4 cells by immunoaffin ity chromatography a.nd 
an alyzed it by immunoblotting. An IS-kDa band co-mig ratin g with 
human recombinant b FGF was detected in both the parent and 
resistan t li n es (Fig 6). In addition, 22- and 24- kDa b ands repre-
senting bFGF arising fro m an alternative translation-initiation site 
[2 5] were also de tected . Densitometric analysis of th e b 3Jlds 
suggested that resistant FSB4 expressed o nly 35% m ore total bFGF 
than pare n ta l ceUs, with n o relative change in isoform expression. 
These observation s su ggest an overaU increase in bFGF production 
or in its stability as opposed to the u se of a m ore efficient initiation 
codon [25] in the FSB4 cells; h owever , it remains to b e ascerta ined 
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F ig ure 5. R esistance can be abrogated by suralnin or neutralizing 
antibodies to FGFs. Survival of SK-M_EL-5 parent cells or FSB4-resistant 
ce lls treated with bFGF-saporin (SA P) (5-150 nl11) and (A) with (c"m'd 
sI/ llnn's) or without (OpCII circles) previous tr~atment with 1 mM suramin; and 
(B) after treatment wi th neutra li zing antibodies (10 mg/ l) to bFGF (rlo.<cd 
rrinIlS,,"s), aFGF (opCI/ trinl/gles), or bFGF plus aFGF (rlost'd cirrlcs). or without 
previous treatlllent (opCI/ circles) . In both panels. parental and r~s i sta\1t cells 
wer~ cultured for 15 h in fresh serum-free medium with or without suramin 
or neutralizing antibod ies before ~XpOSillg cells to bFGF-saporin for 1 h. 
After treatm~nt, the cells were rep lated in duplicate for cell survival assays. 
Afte r 7 d, the ce ll s were suspended ;1I1d coun ted by Coul ter counter. Results 
are expr~ssed as the mean surviving fra ction of treared cells compared with 
un treated controls fi'om thr~e indepelldent experiments (n = 6) . Bm", SEM. 
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Figure 6. Resistant cells contain slightly more bFGF than the 
parental cells . bFGF was immunoprecipitated from parental and resistant 
cells using antibody specific for bFGF and then ana lyzed by chemilulllines-
cent anti-bFGF immunoblotting. Human recombinant bFGF (1 ng) was 
used as a contro l. A 'TOWS indicate positions of the IS-kDa bFGF species 
co-migrating with 1 ng of human recombinant bFGF. as well as the 22- and 
24-kDa species of bFGF. 
whether the observed increase in intrace llul ar bFGF IS alone 
responsible for the resistant phenotype. JOor this reason , we next 
examined the presence of bFGF in cond itioned m edia. Secreted 
bFGF was captured by in cubating monolayer cultures ofSK-MEL-5 
or FSD4 cells overnight with neutralizing an tibody to bFGF, and 
the immune complexes were ana lyzed by anti-bFGF immunoblot-
ting. bFGF proteins had mol ecular weights of 16, 18, 22, and 24 
kDa, and an additional higher molecular weight form not observed 
in intracellul ar assays was detected at approximately 30 kDa in both 
parental SK-MEL-5 and FSD4 cells (Fig 7) . Densitometric ana lysis 
of bFGF proteins revealed that FSD4 secreted 20% to 30% more 
18-kDa and 30-kDa bFGF, but 40% less 22- kDa bFGF th an parent 
ce lls. Whether these d ifferences represent a switch to a more 
biological ly active isofornl in the resistant FSB4 cells is not known. 
We asked next w hether suramin would simil arly restore bFGF-
saporin sensitivity in FSB4 resistant cells ;11 vivo. Nude mi ce bearing 
parental SK-MEL-5 xenografts or FSB4 xenografts, which retain 
resistance to bFGF-saporin (31-125 /.Lg/kg) ;11 V;I/O (Fig SA), were 
treated with suramin intravenously for 3 d before a single intrave-
nous inj ection of bFGF-saporin 5 d after tumor implantation. 
Suramin treatment of anima ls with FSD4 xenografts restored 
bFGF-saporin sensitivity (Fig SB) . This was seen as a greater than 
60% reduction in FSB4 tumor vo lum es as of day 30 after implan-
tation, compared w ith tumor volumes of FSD4-bearing animals 
receiving bFGF-saporin treatment alone (p < 0.05). [n contrast, 
5':> ~V ~ .L~ 0<0 
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Figure 7. Resistant cells secrete bFGFs with different isoform 
ratios than those of parental cells. Cel ls were cultured overnight in 
serum-free medium contain ing bFGF neutralizing antibody covalently 
coupled to sepharose beads. bFGF was dissociated from the beads and 
analyzed by anti-bFGF immunoblotting as in Fig 6. T he positions of the 
molecu lar-weight standards arc indicated. 
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Figure 8. Suramin abrogates FSB4 resistance jll I1jl1o. FS134 or 
SK-MEL-5 tumors were implanted subcutaneously in nude mice. O n each 
of the next 3 d. the an imals received suramin (150 mg/kg) by tail vein 
injection. On day 5. bFGF-saporin (62 /Lg/kg) was administered by ta il VeiJl 
injection. A. 11 0 suramin; bFGF-saporil1 concentrations were: 125 /Lg/kg 
(ope ll 'riallgles). 62 /Lg/kg (opell circles), 31 /Lg/kg (closed 'rjallgles). 1)I3S/0] % 
bovine se rum albumin (vehicle) (closed sqllares) . B. resu lts with suram in : 
sllramin plus bFGF-saporin (closed circles). bFGF-saporin only (01''''' circles) . 
sllramin only (opell sqllares). PBS/01 % bovine se rum albumin (vehicle) 
(closet/ sqllares). Results arc plotted as the mcdians of tumor volumes pooled 
froJl'l two indepcndent experiments. Bars, SEM; n = 3-20 mice per 
treatment group. 
suramin treatment alone did not sign ificantly affect the growth of 
either SK-MEL-5 or FSB4 xenografts compared with vehicle-
ttea ted controls. T hirty days after t umo r implantation , the median 
tumor volumes of bFGF-saporin-treated SK-MEL-5 xenografts 
111easured 22% of vehicl e-treated control tUIno rs, demonstrating 
appJ:oximate ly fourfold g reater scnsitiv ity to b FGF-saporin com-
pare d w ith FSD4 resistant xen ografts (p < 0.0l) . Suramin trea tment 
of SK-MEL- 5 xen ograft-bearin g animals resul ted in initial bFGF-
saporin-mediated tum or reduction comparable to that demon-
stratcd in an ima ls rece iving bFGF-saporin treatment alone. How-
eveJ:, by day 30, these tum ors were more than twice as large as 
tumors in an im als receiving bFGF-saporin alone (p < 0.05). 
DlSCUSSION 
Tn summary, chron ic exposure of SK-MEL-5 human melanoma 
ceUs to bFGF-sapotin provided the se lective pressure that resu lted 
in ou r development of bFGF-saporin res istant cells, fi:om which the 
FSB4 sub)jne was cloned. T he FSD4 line sh owed a sixfold decrease 
in bFGF-sap01;n sensitivity (by IC so) compared with the parental 
VOL. 104 . NO.6 JUN E 1995 
line in colony- form ation assa ys and pron o un ced resistance in nude 
mouse xenografts . The resistance of FSB4 is due to extracellular 
autoCl'in e loops between aFGF, bFGF, and cellular receptors for 
bFGF; these loops down-regulate bFGF receptors and thus favor 
survival of this variant when treated with bFGF-sapori.n . Of course, 
one might find independently isolated subclones that are resistant 
Ilia non-autocrine mechanisms. Based on the theories developed by 
Coldman and Go ldie [26] describing the genetic instability of 
neoplasms and the favored survival of phenotypic or genetic 
variants that are res istant to particular drugs, it is in retrospect not 
surprising that prolonged exposure of SK-MEL-S cells to bFGF-
saporin selected for this resistant subpopulation. Studies presente d 
here confirm that bFGF-saporin resistant cells developed ;11 II;tro 
maintain resistance ;11 11 ;110, and subsequent studies are curre ntly 
underway to develop bFGF-saporin resistance ;11 1) ;110 to detertnil1e 
whether resistance arises from the same m echanism in both mod els. 
Investigations of bFGF-saporin dosing regimens ;11 I);IJO suggest the 
importance of frequent adlTtinistration for optimal therapeutic 
responses:I' Because prolonged exposure to bFGF-saporin ;11 1) ;1) 0 
may simi larly select resistance, investigating bFGF-saporin resis-
t;U1ce and the mechanisms by which it occurs may be crucial to 
developing therapeutic regimens that will prevent or circumvent 
bFGF-saporin treatment failure in neoplastic disease . 
Fina]]y, the ability of suramin to restore ;11 1) ;11'0 sensitivity to 
bPGF-saporin in resistant FSB4 cells through disruptiol.l of the 
bFGF autocrine loop, as indicated by results obtained using nell-
tralizing antibodies to bFGF ;11 11;11'0, suggests that both suramin and 
neutraljz ing antibodies have potential use in combined-modality 
therapy with bFGF-saporin. Preliminary ;11 1) ; 1)0 experiments pre-
sented here demo nstrate that suramin is also effective in restol;ng 
sensitivity to bFGF-saporin in FSB4 xenografts ; however , whether 
the mechanism ;11 1) ;1)0 is the same as we have determined for the 
ill 1) ;1,.0 model has yet to be examined. Besides the ability to bloc k 
receptor- ligand interactions, suramin can inhibit DNA topois011ler-
ase II , certain tyrosine phosphata ses, and lysosomal enzymes [27-
29], anyone of whjch may influen ce mitotoxin sensitivity. Lappi el 
al have reported that bFGF-saporin cytotox icity is inhjbited in the 
presence of suramin ;11 1) ;11'0 [10]; the decreased sensitivity of 
parental xenografts treated with the combination of suramin and 
bFGF-saporin suggests that an antagonistic association m ay exist 
between these agents ;11 1) ;1)0 as well , which minimizes persistent 
anti-tumor activity of bFGF-saporin . Altematively, suramin ma y 
promote malignant cell prolifera tion by activating an autocri.11e loop 
involving transforming growth £1ctor-cy and epidermal growth 
factor receptors [30], both of which are fo und in malignant 
melanoma [31 ,32] and tumor vasculature. W e are currently opti-
mizing therape utic efficacy for preventing and circumventing resis-
tance in malignant m elanoma by using multiple cycles of surami.n 
follow ed by bFGF-sa porin . 
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